Patents Assigned to EP PHARMA, LLC
  • Cannabinoid formulations for inhalation
    Patent number: 10588870
    Abstract: A cannabinoid active agent containing formulation comprising the active agent, an HFA propellant, optionally a terpenoid, and optionally a co-solvent is disclosed. At least two cannabinoids, each of which is required to be present in amounts of at least 20% of the total cannabinoid content of formulation are required to be present. Also disclosed is an inhalation method of administration of the formulation without the use of heat greater than 40° C.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: March 17, 2020
    Assignee: EP Pharma, LLC
    Inventors: Charles Raymond Eck, Christopher L. Pelloni
  • Low-temperature inhalation administration of cannabinoid entities
    Patent number: 10537533
    Abstract: A cannabinoid material as active agent containing formulation comprising the active agent, an HFA propellant, and optionally a co-solvent is disclosed. Also disclosed is an inhalation method of administration of the formulation without the use of heat greater than 50° C.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: January 21, 2020
    Assignee: EP Pharma, LLC
    Inventors: Charles Raymond Eck, Christopher L. Pelloni
  • Low-Temperature Inhalation Administration of Cannabinoid Entities
    Publication number: 20180360772
    Abstract: A cannabinoid material as active agent containing formulation comprising the active agent, an HFA propellant, and optionally a co-solvent is disclosed. Also disclosed is an inhalation method of administration of the formulation without the use of heat greater than 50° C.
    Type: Application
    Filed: July 19, 2018
    Publication date: December 20, 2018
    Applicant: EP Pharma, LLC
    Inventors: Charles Raymond Eck, Christopher L. Pelloni
  • Cannabinoid Formulations For Inhalation
    Publication number: 20180344634
    Abstract: A cannabinoid active agent containing formulation comprising the active agent, an HFA propellant, optionally a terpenoid, and optionally a co-solvent is disclosed. At least two cannabinoids, each of which is required to be present in amounts of at least 20% of the total cannabinoid content of formulation are required to be present. Also disclosed is an inhalation method of administration of the formulation without the use of heat greater than 40° C.
    Type: Application
    Filed: July 25, 2018
    Publication date: December 6, 2018
    Applicant: EP Pharma, LLC
    Inventors: Charles Raymond Eck, Christopher L. Pelloni
  • Low-temperature inhalation administration of cannabinoid entities
    Patent number: 10064821
    Abstract: A cannabinoid material as active agent containing formulation comprising the active agent, an HFA propellant, and optionally a co-solvent is disclosed. Also disclosed is an inhalation method of administration of the formulation without the use of heat greater than 50° C.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: September 4, 2018
    Assignee: EP Pharma, LLC
    Inventors: Charles Raymond Eck, Christopher L. Pelloni
  • Low-Temperature Inhalation Administration of Cannabinoid Entities
    Publication number: 20180000731
    Abstract: A cannabinoid material as active agent containing formulation comprising the active agent, an HFA propellant, and optionally a co-solvent is disclosed. Also disclosed is an inhalation method of administration of the formulation without the use of heat greater than 50° C.
    Type: Application
    Filed: June 27, 2017
    Publication date: January 4, 2018
    Applicant: EP Pharma, LLC
    Inventors: Charles Raymond Eck, Christopher L. Pelloni
  • Low-temperature inhalation administration of cannabinoid entities
    Patent number: 9717683
    Abstract: A cannabinoid material as active agent containing formulation comprising the active agent, an HFA propellant, and optionally a co-solvent is disclosed. Also disclosed is an inhalation method of administration of the formulation without the use of heat greater than 50° C.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: August 1, 2017
    Assignee: EP PHARMA, LLC
    Inventors: Charles Raymond Eck, Christopher L. Pelloni